Heft Robert 4
4 · Ra Pharmaceuticals, Inc. · Filed Apr 3, 2020
Insider Transaction Report
Form 4
Heft Robert
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−22,857→ 0 totalExercise: $2.87Exp: 2026-03-10→ Common Stock (22,857 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $9.90Exp: 2028-06-28→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $22.37Exp: 2027-06-20→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $19.88Exp: 2029-06-11→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
- [F2]Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.